Q1 progress positions Abbott for accelerating growth in 2026

Our cancer diagnostics business, medical devices portfolio and pipeline progress are among key growth drivers. 

In the first quarter, Abbott achieved our earnings per share (EPS) target and completed our acquisition of Exact Sciences. With a new high-growth cancer diagnostics business, continued strength in Medical Devices and Established Pharmaceuticals, and steady progress on new products and clinical trials, we are poised to deliver accelerating growth as we move through the year.   

For the first quarter, Abbott delivered adjusted diluted earnings EPS of $1.15 (GAAP diluted EPS was $0.61), consistent with our guidance and reflecting 6% growth. Sales for the quarter totaled $11.2 billion, a 3.7% increase on a comparable basis(7.8% reported), with growth led by Medical Devices and Established Pharmaceuticals.  

  • Medical Devices sales increased 8.5% on a comparable basis (13.2% reported), led by double-digit increases in Rhythm Management, Electrophysiology and Heart Failure.  
  • Sales in Established Pharmaceuticals grew 9.0% on a comparable basis (13.2% reported), with double-digit growth in several countries across the Latin America and Asia Pacific regions.  
  • Diagnostics sales increased 1.8% on a comparable basis (6.1% reported), with growth in Core Laboratory as well as Cancer Diagnostics, which reflects the acquisition of Exact Sciences, completed on March 23, 2026. Cancer Diagnostics growth was driven by double-digit increases in sales of Cologuard®, a market-leading noninvasive colorectal cancer screening option, as well as sales of Cancerguard®, a multi-cancer screening test launched last year. 
  • Nutrition sales reflect the impact of lower sales volumes and strategic pricing actions implemented in the fourth quarter. We expect those pricing actions as well as new product launches to contribute to improved volume growth in 2026. 

We updated our full-year 2026 guidance2 and now project comparable sales growth of 6.5% to 7.5% and adjusted diluted EPS of $5.38 to $5.58, which reflects $0.20 dilution related to the acquisition of Exact Sciences. 

Our pipeline has been highly productive, and we expect that momentum to continue throughout the year. In Structural Heart, positive  early results from our VERITAS study show clinically meaningful closure rates of the investigational Amulet 360™ Left Atrial Appendage Occluder, designed to reduce risk of stroke in patients with non-valvular AFib. In Diabetes Care, positive results of our FreeDM randomized control trial show that FreeStyle Libre® delivered better glucose outcomes than fingersticks in people with Type 2 diabetes on basal insulin. We also announced a collaboration with AtaCor Medical to develop a next-generation extravascular implantable cardioverter defibrillator designed to deliver defibrillation therapy to people living with life-threatening heart rhythms. 

For full financial data and reconciliation of non-GAAP measures, you can read Abbott's full press release.  

live webcast of Abbott’s Q1 earnings call will take place on April 16 at 8 a.m. Central (9 a.m. Eastern).  

For more information, view a summary of Abbott's earnings highlights and download it here.

References

1Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments received by the Structural Heart business under a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.  

2Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition related expenses, and foreign exchange, which could significantly impact Abbott’s results in accordance with GAAP.  

Forward-Looking Statements  

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. 

Important safety information

AMPLATZER™ AMULET™ LEFT ATRIAL APPENDAGE OCCLUDER

  • AMULET™ STEERABLE DELIVERY SHEATH
  • Rx Only

INDICATION FOR USE

The Amplatzer™ Amulet™ Left Atrial Appendage Occluder is a percutaneous transcatheter device intended to reduce the risk of thrombus embolization from the left atrial appendage (LAA) in patients who have nonvalvular atrial fibrillation and who are at increased risk for stroke and systemic embolism based on CHADS2 or CHA2DS2-VASc scores, are suitable for short term anticoagulation therapy, and have appropriate rationale to seek a non-pharmacologic alternative to oral anticoagulation, taking into consideration the safety and effectiveness of the device.

CONTRAINDICATIONS

The Amplatzer™ Amulet™ Left Atrial Appendage (LAA) Occluder is contraindicated for patients:

  • With the presence of intracardiac thrombus.
  • With active endocarditis or other infections producing bacteremia.
  • Where placement of the device would interfere with any intracardiac or intravascular structures.

POTENTIAL ADVERSE EVENTS

Potential adverse events associated with the device or implant procedure include, but are not limited to, the following: Air embolism; Airway trauma; Allergic reaction; Anemia; Anesthesia reaction (nausea, vasovagal reaction, confusion/altered mental status or other); Arrhythmia; Atrial septal defect; Bleeding; Cardiac arrest; Cardiac tamponade; Chest pain/discomfort; Congestive heart failure; Death; Device embolization; Device erosion; Device malfunction; Device malposition; Device migration; Device-related thrombus; Fever; Hematuria; Hypertension/hypotension; Infection; Multi-organ failure; Myocardial infarction; Perforation; Pericardial effusion; Pleural effusion; Renal failure/dysfunction; Respiratory failure; Seizure; Significant residual flow; Stroke; Thrombocytopenia; Thromboembolism: peripheral and pulmonary; Thrombus formation; Transient ischemic attack; Valvular regurgitation/insufficiency; Vascular access site injury (hematoma, pseudoaneurysm, arteriovenous fistula, groin pain or other); Vessel trauma/injury.

FREESTYLE LIBRE 3 SYSTEM

CAUTION: Federal law restricts this device to sale by or on the order of a physician.

GET INFORMED

  • Before using the App, please review the complete product instructions and safety information in the User's Manual and take a look at the Interactive Tutorial on our website www.FreeStyleLibre.com. Tips for Kids are there too if you need.
  • Be safe and follow the instructions properly. Using the System incorrectly could cause you to miss a severe low or high glucose event and/or make a harmful treatment decision.
  • You'll always find the latest version of the User's Manual, including performance data in the Support section at www.FreeStyleLibre.com. If you need a free printed copy, just call Customer Service: 1-855-632-8658, 7 days a week from 8 a.m. to 8 p.m. Eastern Time; excluding holidays.
  • Talk to your health care professional about how to use your Sensor glucose information to help manage your diabetes.
  • During the first 12 hours of Sensor wear the Sensor may be inaccurate symbol will display, and you cannot use Sensor values to make treatment decisions during this time. Confirm Sensor glucose readings with a blood glucose test before making treatment decisions during the first 12 hours of Sensor wear when you see the Sensor may be inaccurate symbol.

COMPATIBLE SENSORS

You can use Libre app with the FreeStyle Libre 3 Sensor and the FreeStyle Libre 3 Plus Sensor (simply referred to as Libre 3 Sensor and Libre 3 Plus Sensor). Some of the information in the User's Manual and the performance characteristics vary between the Sensors. Please reference the labeling content that applies to your Sensor. Make sure you have a Libre 3 Plus Sensor if you plan to connect with a compatible automated insulin dosing (AID) system.

Libre 3 Sensor

  • 14 day wear
  • Can be used by people age 4 and older
  • Do not use with automated insulin dosing (AID) systems
  • Taking more than 500 mg of Vitamin C per day may affect Sensor readings. This could cause you to miss a severe low glucose event.

Libre 3 Plus Sensor

  • 15 day wear
  • Can be used by people age 2 and older
  • Can be used with compatible automated insulin dosing (AID) systems
  • Taking more than 1000 mg of Vitamin C per day may falsely raise Sensor readings. This could cause you to miss a severe low glucose event. You can take up to 1000 mg of Vitamin C per day and still use the Sensor readings to make treatment decisions.

INDICATION FOR USE

Libre 3 Sensor users:

The FreeStyle Libre 3 Continuous Glucose Monitoring System is a real time continuous glucose monitoring (CGM) device with alarms capability indicated for the management of diabetes in persons age 4 and older. It is intended to replace blood glucose testing for diabetes treatment decisions, unless otherwise indicated.

The System also detects trends and tracks patterns and aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments. Interpretation of the System readings should be based on the glucose trends and several sequential readings over time.

The System is also intended to autonomously communicate with digitally connected devices. The System can be used alone or in conjunction with these digitally connected devices where the user manually controls actions for therapy decisions.

Libre 3 Plus Sensor users:

The FreeStyle Libre 3 Continuous Glucose Monitoring System is a real time continuous glucose monitoring (CGM) device with alarms capability indicated for the management of diabetes in persons age 2 and older. It is intended to replace blood glucose testing for diabetes treatment decisions, unless otherwise indicated.

The System also detects trends and tracks patterns and aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments. Interpretation of the System readings should be based on the glucose trends and several sequential readings over time.

The System is also intended to autonomously communicate with digitally connected devices, including automated insulin dosing (AID) systems. The System can be used alone or in conjunction with these digitally connected devices for the purpose of managing diabetes.

CHECK COMPATIBILITY

  • Libre app is only compatible with certain phones and operating systems. Always check the Phone and OS Compatibility Guide before upgrading your phone or its operating system. This Guide is available in the App's Help Menu and in the Support section on www.FreeStyleLibre.com.
  • Authorized compatible products that you can use with your Sensor are also listed at www.FreeStyleLibre.com. Using your Sensor with products that are not on this list may cause inaccurate glucose readings. If you use a computer, you are responsible for keeping it secure and up to date, for example by using anti-virus software and installing system updates.

CONTRAINDICATIONS

Diathermy: Remove all parts of your System before high-frequency electrical heat (diathermy) treatment. The effect of diathermy on the System hasn’t been tested. The exposure may damage the Sensor, which could impact proper device function and cause inaccurate readings.

Automated Insulin Dosing (AID): The Libre 3 Sensor must not be used with AID systems, including closed loop and insulin suspend systems.

WARNINGS

  • Don't ignore low or high glucose symptoms. Use your blood glucose meter to make treatment decisions when your Sensor readings don’t match your symptoms or expectations. Get medical attention when appropriate.
  • Use your blood glucose meter to make treatment decisions when your Sensor reading doesn’t match how you feel, has no number, or you see the Sensor may be inaccuratesymbol during the first 12 hours of Sensor wear. You cannot use Sensor values to make treatment decisions during the first 12 hours.
  • Choking hazard: The System has small parts that may be dangerous if swallowed.
  • You must have access to a blood glucose monitoring system. One is not provided when you use the App.

CAUTIONS – OVERALL SYSTEM

What to know before using the System:

  • Avoid infection by taking standard precautions for bloodborne pathogens.
  • Don't share the App with another person to avoid confusing glucose information.
  • The App doesn’t share data with your System’s Reader. Before you start a Sensor, you must choose whether to use the Reader or the App with the Sensor. Once you start a Sensor, you cannot switch your device.
  • Make sure that your phone and Sensor Kits are kept in a safe place and under your control. This is important to help stop anyone from accessing or tampering with the System.

Who should not use the System:

  • Don't use in people under the age in the Indications for Use. The System is not cleared for use under this age.
  • Don't use if you are on dialysis or critically ill. The System hasn’t been evaluated in these groups. Sensor readings may be inaccurate.
  • The System hasn’t been evaluated when used with other implanted medical devices, such as pacemakers.

When is Sensor glucose different from blood glucose:

  • Glucose levels in interstitial fluid (what your Sensor measures) can be different from blood glucose levels (what your meter measures). You may notice this when your glucose is changing quickly. For example, after eating, taking insulin, or exercising.

CAUTIONS – APP USE

What to know about the App:

  • Disable your phone’s automatic operating system (OS) updates. Before updating your phone’s OS or the App, check the Phone and OS Compatibility Guide to see if the App is compatible. This Guide is available in the App’s Help menu and also in the Support section on www.FreeStyleLibre.com. Check it regularly to make sure that your phone and OS remain compatible with the App.
  • We may contact you if an App or OS update will make your previously compatible phone incompatible. Make sure that your LibreView account has your current email address to receive important information.
  • After an OS update, open the App and check your device settings to make sure it's working properly. Some OS features may impact your ability to get alarms or glucose readings. For example, if you use the iPhone Screen Time feature, add Libre app to the list of Always Allowed apps to ensure that you receive alarms. Or, if you use an Android phone, don’t use the Android Digital Wellbeing app.
  • If you restart your phone, open the App to make sure it’s working properly.
  • During set up, the App asks for phone permissions. Please allow these. If your phone is not set up properly, you will not be able to use the App and will not get alarms, including the Urgent Low Glucose Alarm. Confirm your settings are as follows:
    • iPhone settings:
      • In the phone settings, keep Bluetooth ON
      • In the phone settings for the App, allow the App to access Bluetooth
      • In the phone settings for the App under Notifications, keep Critical Alerts ON
    • Android phone settings:
      • In the phone settings, keep Bluetooth ON
      • In the phone settings for the App, keep Do Not Disturb access permission ON
      • In the phone settings for the App, keep Nearby Devices permission ON (for Android 12 and above)

Follow the instructions in the App to turn on these settings and permissions. If your phone is not configured correctly, you will see Alarms Unavailable on your screen.

  •  
    • Android users may need to add Libre app to the list of the apps that will not be restricted or put to sleep.
    • If you adjust the phone ringer volume (iPhone) or Media volume (Android) to silent or use the phone do not disturb setting, keep 'Override Do Not Disturb' setting in the App ON for Low Glucose, High Glucose, and Signal Loss Alarms to ensure you receive audible alarms.

For you to receive alarms:

  • Keep your phone charged and turned on.
  • Don't force close the App. The App must be running in the background to get alarms.
  • Always keep your phone within 33 feet of you, with no obstacles between you. The Sensor itself will not issue alarms! If you’re out of range, you may not get alarms. If you want to use the App's optional alarms, keep these turned on.
  • Disconnect headphones or speakers from your phone when not in use. You may miss alarm sounds if you don’t.
  • Remember that if you have accessories connected to your phone (like wireless headphones or a smartwatch), you may get alarms on only one device, not all.

Go to the Alarms section in the user manual to learn more about the App's alarms.

CAUTIONS – SENSOR USE

What to know before you apply the Sensor:

  • The Sensor inserts just under your skin. You may have some bruising or bleeding.
  • Clean your hands before handling the Sensor Kit contents. This will help prevent infection.
  • Carefully follow the instructions to prepare the application site on the back of your upper arm. This will help your Sensor stay on for the full wear time and not fall off early. Wash the site using a plain soap. Then, dry and clean with an alcohol wipe. This removes any oily residue and helps the Sensor stick. Allow the site to air dry before applying the Sensor.
  • Only apply the Sensor to the back of your upper arm. The Sensor may not work properly in other areas. Avoid scars, moles, stretch marks, and lumps. Choose an area that stays mostly flat (no bending or folding) during your day. Keep at least 1 inch away from insulin injection sites.
  • Change sites between Sensors so your skin can recover.

What to know about wearing a Sensor:

  • Your Sensor's product insert tells you how long you can wear your Sensor. Remember to always have your next Sensor on hand before your current one ends so you can keep getting your glucose readings.
  • If your Sensor stops working and you don’t have another Sensor, use another method to check your glucose and make treatment decisions.
  • The App can detect when the Sensor isn’t working properly. It will shut your Sensor off and tell you to replace it. This may happen if the Sensor gets knocked off your body, or if there’s a problem with it. Call us if you receive a Replace Sensor message before the end of your wear time. Customer Service: 1-855-632-8658. Available 7 days a week, 8 a.m. to 8 p.m. Eastern Time; excluding holidays.
  • Some people may be sensitive to the adhesive that keeps the Sensor attached to the skin. If you notice significant skin irritation around or under your Sensor, remove the Sensor. Contact your health care professional before continuing to use the System.
  • Intense exercise may cause your Sensor to loosen due to sweat or Sensor movement. If the Sensor gets loose or its tip comes out of your skin, you may get no readings or unreliable low readings. Remove your Sensor and apply a new one.
  • Don’t attempt to reinsert the old one! Call us if any Sensor gets loose or falls off before the end of your wear time. Customer Service: 1-855-632-8658. Available 7 days a week, 8 a.m. to 8 p.m. Eastern Time; excluding holidays. Don't reuse Sensors. The Sensor and Sensor Applicator are designed for single use. Reuse may result in no glucose readings and infection. Not suitable for re-sterilization. Further exposure to irradiation may cause unreliable low results.
  • If a Sensor breaks in your body, call your health care professional.

How to store the Sensor Kit:

  • Store between 36°F and 82°F. Storing outside this range may cause inaccurate Sensor glucose readings.
  • If you think that the temperature may exceed 82°F (for example, in an un-airconditioned home in summer), you should refrigerate your Sensor Kit. Don’t freeze your Sensor Kit.
  • Store in a cool, dry place. Don’t store in a parked car on a hot day.
  • Store between 10-90% non-condensing humidity.

When to remove the Sensor:

  • If the Sensor is becoming loose or if its tip is coming out of your skin, you may get no readings. Or, you may get unreliable readings that don’t match how you feel. Check to make sure your Sensor is not loose. If it’s loose, remove it and apply a new one. Please call Customer Service.
  • If you think your glucose readings are incorrect or don’t match how you feel, do a blood glucose test on your finger to check your glucose. If the problem continues, remove the Sensor and apply a new one. Call Customer Service: 1-855-632-8658. Available 7 days a week, 8 a.m. to 8 p.m. Eastern Time; excluding holidays.

When not to use the Sensor:

  • Don't use if the Sensor Kit carton or Sensor Applicator look damaged or if tamper label indicates Sensor Applicator has already been opened. Infection may result.
  • Don't use if Sensor Kit contents have expired.

Go to the Applying Your Sensor section in the user manual to learn how to prepare and apply your Sensor.

MRI safety information:

  • You can safely have a 1.5T or 3T MRI exam while wearing your Sensor, under the conditions listed below. Injury may result if the conditions are not followed. Leave your phone and Reader outside of the exam room. Sensor readings may be inaccurate during the MRI, but System function returns fully back to normal after 1 hour.

Parameter

Condition

Device Name

Libre 3 or Libre 3 Plus Sensor

Static Magnetic Field Strength (B0)

1.5T and 3T

MR Scanner Type

Cylindrical

B0 Field Orientation

Horizontal

Maximum Spatial Field Gradient

40 T/m (4,000 G/cm)

Maximum Gradient Slew Rate

200 T/m/s per axis

RF Excitation

Circularly Polarized (CP)

RF Transmit Coil Type

Integrated Whole Body Transmit Coil

Operating Mode

Normal Operating Mode

RF Conditions

Maximum Whole-body SAR: 2 W/kg

Scan Duration

1.5T scanners: Up to 1 hour of continuous scanning without cooling period.

_________________________________________________________________________________

3T scanners: Up to 12 minutes of scanning between the pelvis and the sternum with a cooling period of 2 minutes between scans. Up to 1 hour of continuous scanning without cooling period when scanning elsewhere.

Scan Regions

All landmark locations are acceptable within the region-specific scan durations described above.

Image Artifact

The presence of a Libre 3 or Libre 3 Plus Sensor may produce an image artifact of 5.8 cm. Some manipulation of scan parameters may be needed to compensate for the artifact.

Device Functionality

Device readings may be inaccurate during active MRI scanning but device functionality fully returns to normal operation by 1 hour following MRI exposure.

SECURITY INFORMATION

  • You are responsible for properly securing and managing your phone. If you suspect an adverse cybersecurity event related to the App, contact Customer Service.
  • The App is not intended for use on a phone that has been altered or customized to remove, replace or circumvent the manufacturer’s approved configuration or use restriction, or that otherwise violates the manufacturer’s warranty.
  • Don't use the App on a jailbroken or rooted device. When used on a jailbroken or rooted device or in the case of a potential cybersecurity event, the App will stop without notification. This means you won't receive alarms and will need to use another method to check your glucose. Please contact Customer Service.
  • Use of an unsupported mobile device or OS version may affect App security and functionality. You are responsible for the risks associated with the use of the App on an unsupported mobile device or OS version.
  • The App should only be downloaded and/or updated through authorized distributors, including the App Store (iPhone) and Google Play Store (Android).

INTERFERING SUBSTANCES

Libre 3 Sensor

Taking Vitamin C supplements while wearing the Sensor may falsely raise Sensor glucose readings. Taking more than 500 mg of Vitamin C per day may affect the Sensor readings. This could cause you to miss a severe low glucose event. Vitamin C can be found in supplements including multivitamins. Some supplements, including cold remedies such as Airborne® and Emergen-C®, may contain high doses of 1000 mg of Vitamin C. These should not be taken while using the Sensor. See your health care professional to understand how long Vitamin C is active in your body.

Libre 3 Plus Sensor

Taking more than 1000 mg of Vitamin C per day may falsely raise your Sensor readings. This could cause you to miss a severe low glucose event. Vitamin C can be found in supplements including multivitamins and cold remedies such as Airborne® and Emergen-C®. See your health care professional to understand how long Vitamin C is active in your body.

 

CANCERGUARD TEST

Rx only. The Cancerguard® test is indicated for use in adults ages 50-84 with no known cancer diagnosis in the last three years. It detects alterations in circulating tumor DNA and tumor-associated protein levels which are commonly associated with cancer. The test does not detect all cancers and is not a replacement for existing recommended cancer screening or diagnostic modalities for cancer. Current recommended screening for cancer should also be followed. The test is not indicated for screening of breast and prostate cancer and was not evaluated for the detection of pre-cancerous lesions. Due to the potential for follow-up imaging with IV contrast CT after a positive test result, careful consideration should be given before ordering the Cancerguard test for patients with a history of adverse reactions to iodine based IV contrast or for women who are, may be, or plan to become pregnant. Results should be interpreted in the context of a patient’s medical history, clinical signs, and symptoms. A negative result does not rule out the presence of cancer of any type. A positive Cancerguard™ test result means that the blood test identified a cancer signal that may indicate the presence of cancer. This result alone does not confirm the presence of cancer. Further clinical evaluation by a healthcare provider (which may include blood tests such as complete blood count and comprehensive metabolic panel) and follow-up imaging are needed to locate and confirm a diagnosis of cancer or determine that cancer is not present. While there are no established guidelines for imaging following a positive Cancerguard test result, there is a published follow-up workflow based on expert clinician opinion and results from an exploratory, prospective, interventional study [Kisiel et al Life (Basel) 2024 Jul 24; Lennon et al, Science, 2020]. The proposed workflow in the Kisiel et al publication includes an intravenous-contrast enhanced computed tomography (IV contrast CT of chest, abdomen/pelvis, and soft-tissue neck) and if necessary, positron emission tomography-computed tomography (18F FDG PET-CT) from the skull-base to mid-thigh. Alternative follow-up procedures (e.g. targeted imaging, endoscopic procedures, CT without IV- contrast) may be appropriate in the context of the patient’s medical history and clinical evaluation [Lennon et al, Science, 2020]. False positive and false negative test results can occur.

The Cancerguard test was developed, and the performance characteristics validated by Exact Sciences Laboratories following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. This test has not been cleared or approved by the US Food and Drug Administration. The test is performed at Exact Sciences Laboratories. Exact Sciences Laboratories is accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing.

COLOGUARD

Important Risk Information

Indications for Use

The Cologuard® and Cologuard Plus™ tests are intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. A positive result may indicate the presence of colorectal cancer (CRC) or advanced adenoma (AA)/advanced precancerous lesions (APL) and should be followed by a colonoscopy. The Cologuard test and Cologuard Plus test are indicated to screen adults of either sex, 45 years or older, who are at average risk for CRC. These tests are not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.

Do not use the Cologuard products if you have:

  • Had adenomas, which are a type of colon polyp that can sometimes become cancer
  • inflammatory bowel disease (IBD) or other hereditary syndromes
  • a personal or first-degree family history of colorectal cancer
  • or a positive result from another colon cancer screening method within that test's recommended screening interval.

Talk to your healthcare provider if any of these situations apply to you.

Cologuard results should be interpreted with caution. A positive test result does not confirm the presence of cancer. Patients with a positive test result should be referred for colonoscopy.

A negative test result does not confirm the absence of cancer. Patients with a negative test result should discuss with their healthcare provider when they need to be tested again.

False positives and false negatives can occur. It is important to talk to your doctor about your test results.

Do not provide a sample if you have diarrhea or have blood in your urine or stool.

The risks related to using the Cologuard collection kit are low, with no serious adverse events reported among people in a clinical trial. You should be careful when opening and closing the lids to avoid the risk of hand strain.

Please read the Instructions for Use and talk to your healthcare provider to see if a Cologuard test is right for you. This product is available by prescription only.

Refer to the Cologuard Patient Brochure or the Cologuard Plus Patient Brochure for additional information on the about the benefits and risk of using each version of the Cologuard product for CRC screening.

Loading...